Genotype | Tumor criteria | OR (95%CI) | P value | |
---|---|---|---|---|
Tumor stage | ||||
Early (I and II) (n = 23) | Late (III and IV) (n = 38) | |||
A/A | 2 (8.7%) | 4 (10.5%) | R | |
A/- | 16 (69.6%) | 30 (78.9%) | 0.938 (0.155–5.686) | 0.944 |
-/- | 5 (21.7%) | 4 (10.5%) | 0.4 (0.047–3.424) | 0.403 |
LNs’ involvement | ||||
No (n = 19) | Yes (n = 42) | |||
A/A | 3 (15.8%) | 3 (7.1%) | R | |
A/- | 12 (63.2%) | 34 (81%) | 2.833 (0.502–15.987) | 0.238 |
-/- | 4 (21.1%) | 5 (11.9%) | 1.25 (0.158–9.917) | 0.833 |
Distant metastasis | ||||
No (n = 46) | Yes (n = 15) | |||
A/A | 5 (10.9%) | 1 (6.7%) | R | |
A/- | 34 (73.9%) | 12 (80%) | 1.765 (0.187–16.67) | 0.62 |
-/- | 7 (15.2%) | 2 (13.3%) | 1.429 (0.1–20.437) | 0.793 |
ER receptor status | ||||
Positive (n = 44) | Negative (n = 17) | |||
A/A | 4 (9.1%) | 2 (11.8%) | R | |
A/- | 32 (72.7%) | 14 (82.4%) | 0.875 (0.143–5.346) | 0.885 |
-/- | 8 (18.2%) | 1 (5.9%) | 0.25 (0.017–3.66) | 0.311 |
PR receptor status | ||||
Positive (n = 42) | Negative (n = 19) | |||
A/A | 4 (9.5%) | 2 (10.5%) | R | |
A/- | 30 (71.4%) | 16 (84.2%) | 1.067 (0.176–6.47) | 0.944 |
-/- | 8 (19%) | 1 (5.3%) | 0.25 (0.017–3.66) | 0.311 |
HER2 receptor status | ||||
Positive (n = 28) | Negative (n = 33) | |||
A/A | 2 (7.1%) | 4 (12.1%) | R | |
A/- | 21 (75%) | 25 (75.8%) | 0.595 (0.099–3.579) | 0.571 |
-/- | 5 (17.9%) | 4 (12.1%) | 0.4 (0.047–3.424) | 0.403 |
Ki-67 level | ||||
High (n = 54) | Low (n = 7) | |||
A/- | 40 (74.1%) | 6 (85.7%) | R | |
A/A | 6 (11.1%) | 0 (0%) | 0 | 0.999 |
-/- | 8 (14.8%) | 1 (14.3%) | 0.833 (0.088-7.898) | 0.874 |